Bausch & Lomb (NYSE: BLCO) net income
Bausch & Lomb reported a net loss of $360.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $317.0m. Earnings per share were −$1.02.
Bausch & Lomb's best year of the last 5 was fiscal 2021. The biggest drop was in fiscal 2022, −96.7%. It reported a loss in 3 of those 5 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$360.0m | — | −7.1% | −$1.02 |
| 2024 | −$317.0m | — | −6.6% | −$0.90 |
| 2023 | −$260.0m | −4,433.3% | −6.3% | −$0.74 |
| 2022 | $6.0m | −96.7% | 0.2% | $0.02 |
| 2021 | $182.0m | — | 4.8% | $0.52 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Bausch & Lomb net income compared with its sector
By net income for its latest fiscal year, Bausch & Lomb ranks 459th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Bausch & Lomb, −7.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 457th | Arcus Biosciences | −$353.0m | −142.9% |
| 458th | Jazz Pharmaceuticals | −$356.1m | −8.3% |
| 459th | Bausch & Lomb | −$360.0m | −7.1% |
| 460th | Myriad Genetics | −$365.9m | −44.4% |
| 461st | Zenas BioPharma | −$377.7m | −3,777.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Bausch & Lomb
- How much did Bausch & Lomb earn in fiscal 2025?
- Bausch & Lomb reported a net loss of $360.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $317.0m.
- What are the earnings per share of Bausch & Lomb?
- They were −$1.02 in fiscal 2025, compared with −$0.90 in fiscal 2024.
- What was the most profitable year for Bausch & Lomb?
- Of its last 5 fiscal years, fiscal 2021, with $182.0m.
- Where does Bausch & Lomb rank in its sector by net income?
- It ranks 459th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Bausch & Lomb come from?
- From the annual report (Form 10-K) that Bausch & Lomb files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Bausch & Lomb files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Bausch & Lomb: the Bausch & Lomb page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.